Drug Type Peptide drug conjugates |
Synonyms SBI-PDC01 |
Target |
Action antagonists |
Mechanism TRPV6 antagonists(Transient receptor potential cation channel subfamily V member 6 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Prostatic Cancer | Preclinical | United States | 30 Nov 2022 |





